Silence Therapeutics

Company Overview

Silence Therapeutics is pioneering the development of a new class of medicines by leveraging the body’s natural RNA interference (RNAi) mechanism to suppress the expression of specific target genes implicated in diseases with significant unmet medical needs. The company’s proprietary mRNAi GOLD platform enables the creation of short interfering RNAs (siRNAs) that can precisely target and silence disease-associated genes, particularly in the liver, offering substantial therapeutic potential.

Silence’s portfolio includes wholly owned product candidates such as Zerlasiran (SLN360), aimed at addressing the pressing unmet medical need to reduce cardiovascular risk in individuals with elevated lipoprotein levels from birth, and divesiran, designed to target hematological disorders, including polycythemia vera. Silence maintains collaborative research and development partnerships with leading pharmaceutical companies such as AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others, to further advance its innovative RNAi-based therapies.

Financial Highlights (FY 2024)

Company's Business Segments

• Revenue from Contracts with Customers : This segment includes Research collaboration with Mallinckrodt plc, AstraZeneca, Others.
• Royalties : This segment includes Royalties received from their collobrated companies especially from Germany.